HC Wainwright Issues Optimistic Forecast for TARA Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Investment analysts at HC Wainwright increased their Q2 2026 EPS estimates for shares of Protara Therapeutics in a research note issued on Wednesday, May 13th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.31) for the quarter, up from their previous forecast of ($0.40). HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.24) EPS, FY2027 earnings at ($1.37) EPS, FY2028 earnings at ($0.34) EPS, FY2029 earnings at $0.60 EPS and FY2030 earnings at $1.10 EPS.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.05.

TARA has been the topic of a number of other reports. JPMorgan Chase & Co. reduced their price target on shares of Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, May 14th. Wall Street Zen upgraded shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. TD Cowen restated a “buy” rating on shares of Protara Therapeutics in a research report on Tuesday, March 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.50.

Protara Therapeutics Price Performance

Shares of TARA stock opened at $4.60 on Tuesday. The firm has a market cap of $258.52 million, a P/E ratio of -3.43 and a beta of 1.53. Protara Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.82. The firm has a fifty day moving average of $5.24 and a two-hundred day moving average of $5.70.

Insider Activity

In other news, insider Jacqueline Zummo sold 22,598 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $5.26, for a total value of $118,865.48. Following the transaction, the insider directly owned 95,961 shares in the company, valued at approximately $504,754.86. This trade represents a 19.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 7.60% of the company’s stock.

Institutional Trading of Protara Therapeutics

Several hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC lifted its position in Protara Therapeutics by 1.3% in the 1st quarter. Janus Henderson Group PLC now owns 5,207,011 shares of the company’s stock valued at $27,155,000 after purchasing an additional 65,395 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Protara Therapeutics by 22.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 13,548 shares of the company’s stock valued at $71,000 after purchasing an additional 2,464 shares during the last quarter. Walleye Capital LLC lifted its position in Protara Therapeutics by 204.0% in the 1st quarter. Walleye Capital LLC now owns 443,401 shares of the company’s stock valued at $2,310,000 after purchasing an additional 297,525 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Protara Therapeutics by 133.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 531,267 shares of the company’s stock valued at $2,767,000 after purchasing an additional 304,110 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Protara Therapeutics by 38.7% in the 1st quarter. Bank of New York Mellon Corp now owns 129,671 shares of the company’s stock valued at $676,000 after purchasing an additional 36,149 shares during the last quarter. 38.13% of the stock is currently owned by institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.